- Home
- LX vs AKBA Comparison
LX vs AKBA Comparison
Compare LX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | AKBA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 251.0M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LX | AKBA |
|---|---|---|
| Price | $1.48 | $1.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $4.67 |
| AVG Volume (30 Days) | 3.0M | ★ 4.1M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 18.73% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $0.82 |
| 52 Week High | $7.06 | $3.81 |
Technical Indicators
Market Signals| Indicator | LX | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 46.66 |
| Support Level | $1.41 | $1.16 |
| Resistance Level | $2.06 | $1.52 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 13.86 | 7.59 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.